67 Recruiting Trials

Clinical Trials
for Cancer in Alaska

67 clinical trials for Cancer are currently recruiting participants at study sites in Alaska. Study-related care is provided at no cost.

67
Recruiting trials
27
Study sites
2
Cities
28
Industry-sponsored
20
Phase 2
41
Phase 3

Cancer clinical trials in Alaska: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Alaska, recruiting cancer studies are concentrated in Anchorage and Fairbanks. 28 of the 67 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 67 recruiting Cancer trials in Alaska

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06801834
This trial is looking for patients with extensive stage small cell lung cancer that has been treated before. Participants will receive the study drug sacituzumab govitecan to see how it works compared to standard treatment.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Anchorage, Alaska +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06764875
This trial is looking for individuals with advanced stomach cancer that tests positive for HER2. Participants will receive a combination of rilvegostomig, chemotherapy, and other treatments to see how well it works.
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
PHASE3 Anchorage, Alaska +4 sites NCT07492641
This trial is looking for people with advanced breast cancer who have not been treated for it before. Participants will receive either BGB-43395 with letrozole or a different treatment option with letrozole.
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
PHASE2 Anchorage, Alaska +4 sites NCT06712316
This trial is looking for people with advanced non-small cell lung cancer who have not received any treatment yet. Participants will receive a new treatment combined with chemotherapy and will be monitored for their health outcomes.
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
PHASE3 Anchorage, Alaska +4 sites NCT07214779
This trial is looking for women with a specific type of ovarian cancer that hasn't responded to platinum-based treatments. Participants will receive the drug INCB123667 or a chemotherapy chosen by their doctor.
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3 Anchorage, Alaska +4 sites NCT05774951
This trial is looking for people with early breast cancer who have completed at least 2 years of standard treatment. Participants will receive camizestrant to see if it helps improve their outcomes compared to standard therapy.
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
PHASE3 Anchorage, Alaska +4 sites NCT06824467
This trial is looking for women with certain types of ovarian cancer who have had previous chemotherapy. Participants will receive a treatment to see if it helps them live longer without their cancer worsening.
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
PHASE3 Anchorage, Alaska +4 sites NCT06952504
This trial is looking for people with advanced or recurring endometrial cancer that has specific characteristics. Participants will receive a combination of two medicines, sacituzumab tirumotecan and pembrolizumab, to see if it helps them live longer or keeps the cancer from worsening.
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
PHASE3 Anchorage, Alaska +4 sites NCT07216703
This trial is looking for women with cervical cancer that has spread and cannot be cured with surgery or radiation. Participants will receive a combination of study medicines to help learn how effective and safe they are.
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06793215
This trial is looking for adults with advanced lung cancer that has a specific mutation called KRAS G12C. Participants will be comparing two different treatment combinations to see which one works better.
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
PHASE2 Anchorage, Alaska +4 sites NCT07063745
This trial is looking for people with advanced lung cancer who have a specific genetic change. Participants will receive either a combination of Navlimetostat, pembrolizumab, and chemotherapy or a placebo with the same treatments.
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06899126
This trial is looking for adults with advanced lung cancer that has specific characteristics. Those who qualify will receive a combination of treatments to see how well they work.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Anchorage, Alaska +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3 Anchorage, Alaska +4 sites NCT05812807
This trial is looking for people with early-stage triple-negative breast cancer who had no cancer left after previous treatments. Participants will either continue receiving pembrolizumab or just be monitored after surgery to see which approach works better to prevent cancer from coming back.
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
PHASE2 Anchorage, Alaska +4 sites NCT06161025
This trial is looking for adults with certain types of ovarian, peritoneal, or fallopian tube cancer who have not responded to previous treatments. Participants will receive a new therapy and may need to undergo biopsies and imaging tests during the study.
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
PHASE3 Anchorage, Alaska +4 sites NCT06592924
This trial is looking for men with prostate cancer that has spread and is responding poorly to current treatment. Participants will receive additional medication to see if it helps lower cancer growth and spread.
Recruiting

Where the Cancer studies are in Alaska

  • Alaska Women's Cancer Care, Anchorage28 trials
  • Katmai Oncology Group, Anchorage28 trials
  • Providence Alaska Medical Center, Anchorage28 trials
  • Alaska Oncology and Hematology LLC, Anchorage25 trials
  • Alaska Breast Care and Surgery LLC, Anchorage24 trials
  • Anchorage Associates in Radiation Medicine, Anchorage24 trials

Counts are recruiting studies listing at least one site in Alaska, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Alaska: common questions

How many Cancer clinical trials are recruiting in Alaska?
TrialFinder currently lists 67 recruiting Cancer clinical trials with study sites in Alaska. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Alaska?
Study sites for the Cancer trials listed on this page include Anchorage. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Alaska?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Alaska also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Alaska?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Alaska.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →